×
About 298 results

ALLMedicine™ Acute Myeloblastic Leukemia Center

Research & Reviews  149 results

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide ...
https://doi.org/10.1016/j.leukres.2020.106490
Leukemia Research; Djamai H, Berrou J et. al.

Dec 29th, 2020 - Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kin...

Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a p...
https://doi.org/10.1007/s10006-020-00851-w
Oral and Maxillofacial Surgery; Bumm CV, Folwaczny M et. al.

May 20th, 2020 - Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in ...

Changes in long term survival after diagnosis with common hematologic malignancies in t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221083
Blood Cancer Journal; Pulte D, Jansen L et. al.

May 14th, 2020 - Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (...

PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
https://clinicaltrials.gov/ct2/show/NCT01296178

Apr 8th, 2020 - Primary objectives Optimizing current treatment of AML based on the classification of patients into different risk groups according to parameters cytogenetic and molecular response to treatment and to analyze its effectiveness in terms of survival...

Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunopheno...
https://doi.org/10.1080/10428194.2020.1737685
Leukemia & Lymphoma; Guolo F, Minetto P et. al.

Mar 18th, 2020 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a poor prognosis myeloid malignancy characterized by an atypical phenotype (CD123+, CD56+, and CD4+). We reported that BPDCN-like phenotype (CD123+ and either CD56+ or CD4+ or both) confers p...

see more →

Clinicaltrials.gov  149 results

Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 CEL_Amide ...
https://doi.org/10.1016/j.leukres.2020.106490
Leukemia Research; Djamai H, Berrou J et. al.

Dec 29th, 2020 - Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kin...

Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a p...
https://doi.org/10.1007/s10006-020-00851-w
Oral and Maxillofacial Surgery; Bumm CV, Folwaczny M et. al.

May 20th, 2020 - Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to cases of MRONJ in ...

Changes in long term survival after diagnosis with common hematologic malignancies in t...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221083
Blood Cancer Journal; Pulte D, Jansen L et. al.

May 14th, 2020 - Five-year survival has increased for many hematologic malignancies in the 21st century. However, whether this has translated into greater long-term survival is unknown. Here, we examine 10- and 20-year survival for patients with multiple myeloma (...

PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
https://clinicaltrials.gov/ct2/show/NCT01296178

Apr 8th, 2020 - Primary objectives Optimizing current treatment of AML based on the classification of patients into different risk groups according to parameters cytogenetic and molecular response to treatment and to analyze its effectiveness in terms of survival...

Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunopheno...
https://doi.org/10.1080/10428194.2020.1737685
Leukemia & Lymphoma; Guolo F, Minetto P et. al.

Mar 18th, 2020 - Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a poor prognosis myeloid malignancy characterized by an atypical phenotype (CD123+, CD56+, and CD4+). We reported that BPDCN-like phenotype (CD123+ and either CD56+ or CD4+ or both) confers p...

see more →